Vestcor Inc Has $22.70 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Vestcor Inc increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 3.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 21,590 shares of the biopharmaceutical company's stock after purchasing an additional 654 shares during the period. Regeneron Pharmaceuticals makes up approximately 0.7% of Vestcor Inc's investment portfolio, making the stock its 25th largest holding. Vestcor Inc's holdings in Regeneron Pharmaceuticals were worth $22,696,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. M&T Bank Corp grew its holdings in shares of Regeneron Pharmaceuticals by 4.3% in the 3rd quarter. M&T Bank Corp now owns 5,480 shares of the biopharmaceutical company's stock valued at $5,761,000 after buying an additional 224 shares during the period. Groupama Asset Managment raised its holdings in shares of Regeneron Pharmaceuticals by 7.0% in the third quarter. Groupama Asset Managment now owns 71,277 shares of the biopharmaceutical company's stock valued at $74,929,000 after purchasing an additional 4,648 shares during the last quarter. Nomura Asset Management Co. Ltd. increased its stake in Regeneron Pharmaceuticals by 4.5% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 86,004 shares of the biopharmaceutical company's stock valued at $90,411,000 after buying an additional 3,698 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in Regeneron Pharmaceuticals during the third quarter worth about $9,908,000. Finally, MML Investors Services LLC raised its stake in shares of Regeneron Pharmaceuticals by 13.9% during the 3rd quarter. MML Investors Services LLC now owns 5,315 shares of the biopharmaceutical company's stock worth $5,587,000 after purchasing an additional 648 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

Analyst Ratings Changes

Several analysts have issued reports on REGN shares. Barclays dropped their price target on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating on the stock in a research report on Friday, November 1st. Wolfe Research began coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an "outperform" rating and a $1,150.00 target price on the stock. Oppenheimer reduced their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating for the company in a report on Wednesday, November 6th. Truist Financial cut their price objective on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a "buy" rating for the company in a research report on Friday, November 1st. Finally, Leerink Partnrs lowered Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $1,099.90.

Regeneron Pharmaceuticals Price Performance

REGN traded down $9.50 on Tuesday, reaching $778.50. The stock had a trading volume of 1,298,463 shares, compared to its average volume of 553,082. The company has a market capitalization of $85.55 billion, a price-to-earnings ratio of 19.27, a price-to-earnings-growth ratio of 3.00 and a beta of 0.08. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. The firm has a 50-day moving average of $871.59 and a 200-day moving average of $1,010.52. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $735.95 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.